Roots Analysis
Cancer Biomarkers Market Professional Survey Report 2021-2030
Covid-19 Updates | Cancer Biomarkers Market for TMB, MSI / MMR and TILs is estimated to be worth USD 860 million in 2030, predicts Roots Analysis
Advances in biotechnology have enabled the identification of several novel biomarkers, which are presently being used for a variety of purposes, including diagnosis, drug development, clinical research and to facilitate therapy-related decisions
COVID-19 AR / VR based Healthcare Digital Marketing Service Providers Market: Demand, Overview, Price And Business Opportunities
Given the present scenario, many stakeholders are adopting such advanced marketing strategies to drive better consumer engagement through the use of immersive and interactive technologies
Roots Analysis has announced the addition of “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” report to its list of offerings.
Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes. These technologies have been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors. Given the increasing demand for immersive technologies in the healthcare and pharma marketing, several stakeholders are expected to forge alliances with AR / VR service providers in the foreseen future. Owing to the rising interest of big pharma players in this domain, we expect an escalated industry-wide adoption of such technologies.
Key Market Insights
More than 125 companies claim to offer different AR / VR based digital marketing services to the healthcare and pharma industry
The majority of players engaged in providing AR / VR based digital marketing services to the healthcare and pharmaceutical industry are small-sized companies (63%), followed by mid-sized (32%) and large players (5%). In addition, majority (38%) of the players were established during the period 2011-2015.
Several big pharma players have taken significant strides in in the field of AR / VR
These instances are either by collaborating with digital marketing service providers or through development of in-house capabilities. Majority (18%) of the instances were recorded in the year 2018.
More than 350 industry players have been identified as likely partners for AR / VR based digital marketing service providers
The potential strategic partners have been identified by evaluating more than 4,500 industry sponsored clinical trials (including phase I / II, phase II and phase II / III trials), and have been analyzed based on our proprietary scoring criteria.
Currently, a significant proportion (57%) of service revenues is generated from AR based digital marketing projects
In 2020, VR based projects are anticipated to contribute to 42% of the overall market share. It is worth mentioning that, in the foreseen future, service revenues generated through MR based technologies are anticipated to grow at a CAGR of 5% till 2030.
The USD 3.04 billion (by 2030) financial opportunity within the AR / VR based healthcare digital marketing service providers market has been analyzed across the following segments:
Type of Technology
- AR Based Services
- MR Based Services
- VR Based Services
Type of product
- Hardware
- Software
End-User
- Large Companies
- Small and Mid-sized Companies
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
The research includes detailed profiles of key players engaged in this domain; each profile features an overview of the company, recent developments and an informed future outlook.
- ARWorks
- CG Life
- CubeZoo
- Impact XM
- INVIVO Communications
- Mirum
- Pixacore
- Random42
- Quast Media
- Tipping Point Media
- vStream
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/healthcare-digital-marketing/323.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Global Digital Therapeutics Market Professional Survey Report 2020-2030
Recent advances in information technology and biomedical science have enabled the development of a number of versatile digital solutions that are capable of either mimicking or augmenting, the fundamental qualities of pharmacological interventions
Roots Analysis has announced the addition of “Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030 (Based on Type of Solution (Software Solution, Gaming Solution and Combination Solution), Type of Therapy (Curative and Preventive), and Purpose of Solution (Medication Replacement and Medication Augmentation” report to its list of offerings.
According to experts, digital therapeutic solutions are primarily based on behavior modification and are designed to address a variety of therapeutic needs across a wide range of disease indications. On the other hand, several digital solutions have been developed to enable remote doctor-patient consultations. Such solutions witnessed a surge in adoptions amidst the COVID-19 pandemic.
Key Market Insights
Nearly 230 digital therapeutic solutions are currently available / under development
Close to 45% of the aforementioned solutions are standalone software applications targeting more than 60 unique indications.
Over 85% of digital therapeutic solutions are intended to replace medication
Such solutions are currently available / being developed to treat neurological disorders (27%), mental health problems (24%), and certain metabolic disorders (24%). Alternatively, some digital health products are designed to augment the effect of conventional therapeutics and are currently being considered for treating substance use disorders and few mental health problems.
220+ clinical trials, focused on digital therapeutics, have been registered since 2004
Around 80,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy of digital therapeutics, and generate real world evidence concerning their efficacy and safety. Close to 50% of such trials have been / are being conducted in the US.
Nearly USD 1.9 billion invested by both private and public investors in this domain
~85% of the total capital raised for digital therapeutics-related initiatives was from venture capital investors, featuring over 370 participants.
Partnership activity in this field has grown at a CAGR of ~42%, between 2015 and 2019
More than 70% of the reported deals were established after 2017, with the maximum activity being reported in 2019. Majority of the instances captured in the report were focused on pilot product offering (29%) and research and development agreements (21%).
North America and Europe are anticipated to capture over 70% of the market share by 2030
The market in Asia-Pacific regions is anticipated to grow at a relatively faster pace (23.2%). In 2030, digital solutions targeting metabolic disorders are likely to represent the largest market share, in terms of revenues from product sales (26%), followed by those intended for mental health problems (20%) and neurological disorders (19%).
The USD 8.86 billion (by 2030) financial opportunity within the digital therapeutics market has been analyzed across the following segments:
Type of Solution
- Standalone Software Application
- Software Application + Device + Personal Coach
- Software Application + Device + AI Support
- Software Application + Device
- Software Application + AI Support
- Software Application + Personal Coach
- Other Types of Solutions
Purpose of Solution
- Medication Replacement
- Medication Augmentation
Type of Therapy
- Curative
- Preventive
Business Model
- Business to Consumer (Patients and Caregivers)
- Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)
Therapeutic Areas
- Cardiovascular Disorders
- Chronic Pain
- Mental Health Problems
- Metabolic Disorders
- Neurological Disorders
- Respiratory Disorders
- Sleep Disorders
- Substance Use Disorders
- Others
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the world
The research covers brief profiles of key players engaged in the development of digital therapeutic solutions; other popular industry players featured in the report include:
- Akili Interactive
- Beats Medical
- Big Health
- Bold Health
- Click Therapeutics
- CureApp
- dreem
- Ehave
- Ginger
- Happify Health
- inMotion VR
- Kaia Health
- Lark Health
- Mahana Therapeutics
- MindMaze
- Noom
- NOVOSI
- Omada Health
- Palo Alto Health Sciences
- Pear Therapeutics
- Vida Health
- Welldoc
- ZOLL Medical
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Macrocycle Drug Discovery Services Market Headed for Growth and Global Expansion by 2030
Given the recent developments in healthcare, supporting safety and efficacy of peptide and affiliated macrocycle drugs, the industry is presently witnessing an increase in discovery and development initiatives related to such therapeutic modalities.
Roots Analysis has announced the addition of “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report to its list of offerings.
The report features an extensive study on the current market landscape and future of companies offering services for peptides and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the report includes:
- A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services
- An insightful geographical benchmarking of the capabilities of companies of various sizes, highlighting the key focus areas, comparing their existing strengths both within and beyond their respective peer groups (based on geography and company size).
- An in-depth analysis of peptide platform and library service providers, featuring information on their company details, purpose of the platform, type of peptide manufactured and platform access model.
- Profiles of peptides and macrocycle drug discovery service providers, featuring information on the year of establishment, location of headquarters, peptide discovery service / platform portfolio, recent developments, and an informed future outlook.
- An analysis of the partnerships that have been established in the recent past, covering mergers and acquisitions, research collaborations, R&D agreements, licensing agreements (related to both technology platforms and service providers) and other form of collaborations.
- An analysis of proprietary display technologies developed by different drug discovery technology providers, based on the 2X2 matrix.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of peptides
- Synthetic peptides
- Biologic and recombinant peptides
Type of discovery steps
- Target identification and validation
- Hit identification
- Lead generation
- Lead optimization
Therapeutic Area
- Oncological disorders
- Metabolic disorders
- Cardiovascular disorders
- Infectious diseases
- Urological disorders
- Endocrine disorders
- CNS disorders
- Other diseases
Company Size
- Small companies
- Mid-sized companies
- Large and very large companies
Key geographical regions
- Europe
- North America
- Asia-Pacific and the Rest of the World
Key companies covered in the report
- GenScript
- JPT Peptide Technologies
- CPC Scientific
- IRBM
- Creative Peptides
- Pepscan
- Interprotein
- RA Pharmaceuticals
- Pepticom
- PeptiDream
- Creative Biolabs
- MeSCue-Janusys
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle%20discovery/300.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Elastomeric Closures Market is Expected to Reach 9.3 billion by 2030
Roots Analysis has done a detailed study on Elastomeric Closure Components Market For Vials, Cartridges and Syringes, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- The elastomeric container closures market is fragmented, featuring the presence of a large number of established players; a relatively larger proportion of small-sized players are based in developing geographies
- Currently, there are over 240 closures, fabricated using a variety of elastomeric materials, available for use in parenteral primary packaging containers; majority of these products are available in the ready-to-use format
- Over time, companies have established preferences regarding fabrication materials for container-closure systems for different drug classes in order to ensure that their products are free from chemical impurities
- A number of conferences related to pharmaceutical packaging have been organized in the recent past; in addition, stakeholders have also entered into strategic agreements to strengthen their product portfolios
- In order to cope up with emerging trends in the pharmaceutical packaging market, it is important for container closure manufacturers to improve existing practices to cater to the changing needs of drug developers
- The global demand for elastomeric closures is presently driven by rising adoption of parenteral containers; in future, pre-sterilized and coated closures are anticipated to drive the demand at a relatively faster pace
- The overall market is poised to grow steadily; the opportunity is likely to be well-distributed across various types of containers, types of closures and regions
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Chapter Overview
- Pharmaceutical Packaging
- Types of Pharmaceutical Packaging
- Innovation in Pharmaceutical Packaging
- Traditional Aseptic Pharmaceutical Filling Operations
- Limitations of Traditional Primary Packaging
- Role of Containers-Closures Systems in Pharmaceutical Packaging
- Types of Closures Used in Pharmaceutical Packaging
- Closures for Prefilled Syringes / Syringes
- Closures for Vials
- Closures for Cartridges
- Key Considerations for Choosing Materials for Fabricating Closures
- Elastomeric Packaging Materials
- Key Properties of Elastomeric Packaging Materials
- Popular Types of Elastomeric Packaging Materials
- Regulatory Guidelines for Elastomeric Closures
- Manufacturing Process for Elastomeric Closures
- Quality Assessment Tests for Elastomeric Closures
- Advantages and Limitations of Elastomeric Packaging Materials
- Concluding Remarks
- MARKET LANDSCAPE
- Chapter Overview
- Elastomeric Closures for Parenteral Containers: List of Products
- Analysis by Type of Closure
- Analysis by Type of Closure and Headquarters of Manufacturer
- Analysis by Type of Closure and Size of Player
- Analysis by Type of Container
- Analysis by Type of Elastomeric Material
- Analysis by Drug Class
- Analysis by Sterilization Status
- Analysis by Sterilization Technique
- Analysis by Type of Coating
- Analysis by Type of Closure
- Elastomeric Closures for Parenteral Containers: List of Manufacturers
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Location of Headquarters
- Analysis by Target Market
- Analysis by Scale of Production
- Leading Manufacturers: Analysis by Number of Products
- Manufacturer Landscape: Analysis by Company Size and Location of Headquarters
- Elastomeric Closures for Parenteral Containers: Recent Initiatives of Players
- Concluding Remarks
- COMPANY PROFILES
- Chapter Overview
- Key Players Based in North America
- Aptar Pharma (a Part of AptarGroup)
- Company Overview
- Financial Information
- Product Portfolio
- Recent Developments and Future Outlook
- DWK Life Sciences
- Company Overview
- Product Portfolio
- Recent Developments and Future Outlook
- West Pharmaceutical Services
- Company Overview
- Financial Information
- Product Portfolio
- Recent Developments and Future Outlook
- Key Players Based in Europe
- Datwyler Sealing Solutions (a Part of Datwyler Group)
- Company Overview
- Financial Information
- Product Portfolio
- Datwyler Sealing Solutions (a Part of Datwyler Group)
- Aptar Pharma (a Part of AptarGroup)
5.3.1.4 Recent Developments and Future Outlook
- Lonstroff (a Part of Sumitomo Rubber Industries)
- Company Overview
- Financial Information
- Product Portfolio
- Recent Developments and Future Outlook
- Ompi (a Part of Stevanato Group)
- Company Overview
- Product Portfolio
- Recent Developments and Future Outlook
- Key Players Based in Asia-Pacific
5.4.1 Daikyo Seiko
- Company Overview
- Product Portfolio
- Recent Developments and Future Outlook
- Hebei First Rubber Medical Technology (a Part of DESHENG Group)
- Company Overview
- Product Portfolio
- Recent Developments and Future Outlook
- Jiangsu Hualan New Pharmaceutical Material
- Company Overview
- Product Portfolio
- Recent Developments and Future Outlook
- PACKAGING TRENDS ANALYSIS FOR RECENTLY APPROVED DRUGS
- Chapter Overview
- List of Approved Drugs (2014-2018)
- Analysis by Year of Approval
- Analysis by Type of Molecule
- Analysis by Type of Biologic
- Analysis by Holding Temperature Range
- Analysis by Type of Container
- Analysis by Type of Container and Year of Approval
- Analysis by Type of Container and Type of Molecule
- Analysis by Type of Container and Dosage Form
- Analysis by Type of Container and Route of Administration
- Analysis by Type of Container and Holding Temperature Range
- Popular Type of Material Used for Containers
- Analysis by Type of Closure
- Analysis by Type of Closure and Year of Approval
- Analysis by Type of Closure and Type of Molecule
- Analysis by Type of Closure and Dosage Form
- Analysis by Type of Closure and Route of Administration
- Analysis by Type of Closure and Holding Temperature Range
- Popular Type of Material Used for Closures
- Analysis by Type of Elastomeric Material Used for Closures and Dosage Form
- Analysis by Type of Elastomeric Material Used for Closures and Route of Administration
- Analysis by Type of Elastomeric Material Used for Closures and Holding Temperature Range
- Analysis by Type of Elastomeric Material Used for Closures
- Most Active Players: Analysis by Number of Drugs Packaged Using Elastomeric Closures
- Concluding Remarks
- RECENT DEVELOPMENTS
- Chapter Overview
- Pharmaceutical Packaging Industry: Partnership Activity
- Partnership Models
- List of Partnerships and Collaborations
- Analysis by Year of Partnership
- Analysis by Type of Partnership
- Analysis by Focus Area
- Most Active Players: Analysis by Number of Partnerships
- Elastomeric Container Closures in Pharmaceutical Packaging Industry: Recent Expansions
- Pharmaceutical Packaging Industry: Recent Conferences
- List of Recent Conferences
- Analysis by Year of Occurrence
- Analysis by Geography
- Elastomeric Container Closures: List of Recent Conferences
- Analysis by Focus Area / Agenda
- Geographical Mapping of Conferences
- List of Recent Conferences
- Concluding Remarks
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Biopharmaceutical Contract Manufacturing Market is anticipated to grow at a CAGR 13% by 2030
Roots Analysis has done a detailed study on China Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products
- Several players provide one-stop solutions and are capable of operating at various scales; the landscape includes a mix of both established players and new entrants
- In order to cater to the evolving needs of clients / sponsors, CMOs have established facilities across different regions of China; Eastern China, with the maximum number of sites, has emerged as a manufacturing hub
- With over 80 deals inked in past five years, there has been a surge in the partnership activity within this domain; majority of these collaborations were signed for the development and manufacturing of antibody-based products
- Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics
- We expect global biopharmaceutical developers to continue to outsource their manufacturing operations to China in the long term; we anticipate the CMO industry in the region to grow at an annualized rate of ~13%, till 2030
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Chapter Overview
- Overview of Biopharmaceuticals
- Manufacturing of Biopharmaceuticals
- Types of Expression Systems Used
- Bacterial Expression Systems
- Yeast Expression Systems
- Insect Expression Systems
- Plant Expression Systems
- Mammalian Expression Systems
- Fungal Expression Systems
- Processing Steps
- Upstream Processing
- Downstream Processing
- Overview of Contract Manufacturing
- Contract Manufacturing Scenario in China
- Need for Outsourcing in the Biopharmaceutical Industry
- Biopharmaceutical Outsourcing in China: Regulatory Scenario
- Commonly Outsourced Operations in the Biopharmaceutical Industry
- Basic Guidelines for Selecting a CMO Partner
- Advantages of Outsourcing Manufacturing Services
- Benefits of Engaging Chinese Contract Service Providers
- Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
- Challenges Associated with Engaging Chinese Contract Service Providers
- Future Perspective
- Types of Expression Systems Used
- CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
- Chapter Overview
- Small Molecule and Large Molecule Drugs / Therapies
- Comparison of Key Characteristics
- Comparison of Manufacturing Processes
- Comparison of Key Manufacturing-Related Challenges
- COMPETITIVE LANDSCAPE
- Chapter Overview
- Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Scale of Operation
- Analysis by Location of Headquarters
- Analysis by Location of Manufacturing Facilities
- Analysis by Type of Product
- Analysis by Types of Services Offered
- Analysis by Type of Biologic
- Analysis by Expression System Used
- Analysis by Type of Bioreactor Used
- Analysis by Mode of Operation of Bioreactor
- Analysis by Packaging Form Used
- Analysis by Regulatory Accreditations / Certifications
- COMPANY PROFILES
6.1 Chapter Overview
6.2 ChemPartner Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Recent Developments and Future Outlook
6.3. JHL Biotech
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Recent Developments and Future Outlook
6.4. JOINN Biologics
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Recent Developments and Future Outlook
6.5 MabPlex
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Recent Developments and Future Outlook
6.6. Mycenax Biotech
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Recent Developments and Future Outlook
6.7. WuXi AppTec
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Service Portfolio
6.7.4. Manufacturing Facilities and Capabilities
6.7.5. Recent Developments and Future Outlook
- PARTNERSHIPS
7.1 Chapter Overview
7.2. Partnership Models
7.3. Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Therapeutic Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.9. Geographical Distribution by Number of Partnerships
7.3.10. Intercontinental and Intracontinental Agreements
- RECENT EXPANSIONS
- Chapter Overview
- Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions
- Analysis by Year of Expansion
- Analysis by Type of Expansion
- Analysis by Scale of Operation
- Analysis by Type of Biologic
- Analysis by Location of Expansion Project
- Analysis by Capacity of Expanded Facility
- Most Active Players: Analysis by Number of Expansions
- Analysis by Region
- CLINICAL TRIAL ANALYSIS
- Chapter Overview
- Scope and Methodology
9.3 Clinical Trial Analysis: Biologic Drugs
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Trial Status
9.3.4. Geographical Analysis by Number of Clinical Trials
9.3.5. Geographical Analysis by Enrolled Patient Population
9.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
9.3.7. Analysis of Enrolled Patient Population by Trial Phase
9.3.8. Analysis by Type of Sponsor / Collaborator
9.3.9. Most Active Players: Analysis by Number of Registered Trials
9.3.10. Analysis by Clinical Trial Center
- REGIONAL CAPABILITY ANALYSIS
- Chapter Overview
- Assumptions and Key Parameters
- Overall Landscape of Chinese Biopharmaceutical Contract Manufacturers
- Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China
- Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
- Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
- Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
RNAi therapeutics Market is anticipated to grow at a CAGR 45% by 2030
The recent approval of first RNAi therapeutic, ONPATTROTM, has caused a surge in interest of the industry / non-industry players in upcoming field of pharmacological research
Roots Analysis has announced the addition of “RNAi Therapeutics Market (2nd Edition), 2019-2030” report to its list of offerings.
Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
Key Market Insights
Over 170 RNAi therapeutics are currently under development
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
More than 70% of ongoing clinical trials are being conducted in North America and Europe
In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.
Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014
Majority of these were patent applications (59%), followed by granted patents (40%). It is worth highlighting that both industry and non-industry players are actively involved in this domain. However, majority of the patents related to RNAi therapeutics were filed / granted by industry players (58%).
USD 5.4+ billion invested by both private and public investors, since 2014
Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019. Further, there have been five instances of debt financing, accounting for more than USD 844 million in financing of RNAi therapeutics related initiatives.
Around 65 partnerships were inked since 2014
Maximum number of deals were reported in 2018. Around 30% of the deals were related to the R&D agreements; this was followed by technology licensing agreements (27%).
RNAi therapeutics market is anticipated to increase at a CAGR of over 45% between 2019-2030
This growth is anticipated to be primarily driven by the target specificity of the drug candidates. North America (primarily the US) are expected to capture the majority share by 2030.
The USD 10 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:
Key therapeutic areas
- Oncological disorders
- Infectious diseases
- Genetic disorders
- Ophthalmic disorders
- Hepatic disorders
- Respiratory disorders
Type of RNAi molecule
- siRNA
- miRNA
- shRNA
- sshRNA
- DNA
Route of administration
- Subcutaneous
- Intravenous
- Intradermal
- Intratumoral
- Intravitreal
- Oral
- Intramuscular
Key geographical regions
- North America
- Europe
- Asia Pacific and the Rest of the World
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Preventive Vaccines Market Worth USD 94 billion by 2030 | Roots Analysis
Although vaccines were solely responsible for the global eradication of smallpox (1980) and polio (2015), several vaccine-preventable diseases, such as measles and mumps, are still a threat; COVID-19 has been recently added to the list
Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Preventive Vaccines Market, 2020-2030”.
The report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:
- A detailed assessment of the current market landscape, featuring clinical-stage preventive vaccines.
- A competitiveness analysis of preventive vaccine developers, featuring insightful pictorial summaries and representations.
- Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific.
- An in-depth analysis of the completed, ongoing and planned trials of various preventive vaccines.
- An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, Ebola virus disease, HIV/AIDS, malaria and zika virus infection.
- An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March).
- A case study on contract manufacturing landscape for vaccines, featuring the CMOs engaged in this domain.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Route of Administration
- Intramuscular
- Subcutaneous
- Oral
- Intravenous
- Others
Type of Vaccine
- Pneumococcal Conjugate Vaccine
- Human Papilloma Virus Vaccine
- Rotavirus Vaccine
- Influenza Vaccine
- MMR Vaccine
- Tetanus and Diphtheria Booster Vaccine
- Varicella Vaccine
- DTaP-Hib-IPV Vaccine
- DTaP-HepB-Hib-IPV Vaccine
- Others
Type of Vaccine API
- Live, Attenuated Vaccine
- Inactivated Vaccine
- Conjugate Vaccine
- Subunit Vaccine
- Toxoid Vaccine
- Others
Target Patient Population
- Pediatric Patients
- Adults
Key Players
- GlaxoSmithKline
- Merck
- Sanofi Pasteur
- Pfizer
- Emergent BioSolutions
- CSL
- Others
Key Geographical Regions
- North America
- Europe
- Asia Pacific
- Rest of the World
Key companies covered in the report
- Bio Farma
- Emergent BioSolutions
- GC Pharma
- GlaxoSmithKline
- Janssen
- Merck
- Novavax
- Pfizer
- Sanofi Pasteur
- Valneva
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Next Generation Contact Lenses Market, Forecast to 2030
The “Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030” report features an extensive study of the current market landscape of therapeutic contact lenses, drug-eluting contact lenses, diagnostic / monitoring contact lenses and visual prostheses.
To order this 400+ page report, which features 240+ figures and 200+ tables, please visit this link
Key Inclusions
- A detailed review of the landscape of novel ophthalmic products, highlighting the different categories of contact lenses and visual prostheses (bionic eye technologies) developed / being developed by various players across the world. It features information on the purpose of development (therapeutic, drug delivery, and diagnosis / monitoring), current development status, target indication(s), type of product, type of organization (industry or non-industry) and location of company headquarters.
- An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely ChromaGen™, CUSTOMFLEX® ARTIFICIALIRIS, EYEMATE®, Hyper-CL™, Implantable Miniature Telescope and SENSIMED Triggerfish®.
- Brief profiles of the novel technologies that are being developed to expand the functionality of contact lenses; each profile features an overview of the technology, along with details on its working mechanism, information on application areas, type of products, key benefits, technical specifications and important details related to the developer company.
- An in-depth analysis of the various patents granted / filed related to next generation contact lenses and visual prostheses since 2013, highlighting the prevalent and emerging related to the innovation in this domain. The analysis takes into consideration the type of patent, regional applicability, CPC classification, emerging focus areas, leading industry / non-industry players (in terms of the number of patents filed / granted), and patent valuation.
- An analysis of the partnerships that have been established in this domain, covering R&D agreements, product development agreements, product commercialization agreements, service alliance and acquisitions; the analysis is based on multiple parameters, such as the type of agreement, type of organization, and focus area in terms of product application and target indication.
- A study of prevalent and emerging trends, and the popularity of next generation contact lenses and visual prostheses, as observed on the social media platform, Twitter. The analysis takes into consideration the tweets posted on the platform, between 2013 and 2018 (till mid-October).
- A list of key opinion leaders (KOLs) in this domain, featuring a 2X2 analysis to assess the relative experience of certain individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs based on number of publications, number of citations, number of clinical trials, number of affiliations and extent of professional network.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of Product
- Contact Lenses
- Visual Prostheses
Type of Lenses
- Therapeutic Contact Lenses
- Drug-eluting Contact Lenses
- Diagnostics and Monitoring Contact Lenses
Target Indication
- Age-related Macular Degeneration
- Aniridia
- Diabetes
- Glaucoma
- Retinitis Pigmentosa
Key Geographical Region
- North America
- EU5
- Asia-Pacific
The report includes detailed transcripts of discussions held with the following experts:
- Michal Shavit (Head of Sales and Marketing, EyeYon Medical)
- Mark E. Byrne (Co-Founder and Chief Technical Officer, OcuMedic)
- Praful Doshi (Founder, Chief Executive Officer and Chief Technical Officer, Leo Lens Technology)
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Medical Device CMOs Market Research Report 2020-2030
The “Medical Device CMOs Market, 2019-2030” report features a comprehensive study on the current landscape of contract manufacturing service providers focused on medical devices (specifically for drug-delivery devices, diagnostic devices and therapeutic devices).
Key Inclusions
- A detailed review of the overall landscape of the medical device contract manufacturing market, featuring a list of CMOs engaged in this domain, and detailed analysis based on a number of relevant parameters, such as year of establishment, size of employee base, manufacturing facilities, geographical location, type of device manufactured (drug-delivery devices, diagnostic devices, therapeutic devices and others), scale of operation (precommercial and commercial) and types of services offered ([A] production services (such as design services, prototyping, component manufacturing, packaging, and sterilization), [B] post-production services (such as supply chain management services, labeling services, logistics, and shipping services) and [C] other services (such as regulatory services, project management services and documentation services).
- An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval, across different countries. The report also features an insightful multi-dimensional bubble analysis, featuring a comparison of the contemporary regulatory scenario in key geographies across the globe.
- A benchmark analysis, highlighting the key focus areas of small-sized, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
- An analysis of the medical device supply-chain, highlighting the role of CMOs engaged in this domain and analysis based on services offered, such as supply chain management services, logistics services, shipping services and warehousing services, to medical device companies.
- Elaborate profiles of popular players that specialize in providing services for both precommercial and commercial scale manufacturing of medical devices. Each profile features an overview of the company, its service portfolio, details on manufacturing facilities, as well as an informed future outlook.
- A geographical clinical trial analysis of ongoing and planned studies related to medical devices, featuring details related to medical devices being investigated across various geographies, based on the number of registered trials, current status of trials, phase of development, type of sponsor, therapeutic area(s) and target disease indication(s), and number of patients enrolled.
- A detailed analysis of the mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2014-2019. The analysis provides information on the key value drivers for these mergers and acquisitions and the corresponding acquisition deal multiples. In addition, the analysis features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
- An elaborate discussion on the future opportunities / trends related to the medical device contract manufacturing market that are likely to influence the growth within this domain over the coming years.
- A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall medical device CMO industry.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Application areas
- Therapeutic devices
- Diagnostic devices
- Drug delivery devices
- Other devices
Device class
- Class I medical devices
- Class II medical devices
- Class III medical devices
Therapeutic areas
- Cardiovascular disorders
- CNS disorders
- Metabolic disorders
- Oncological disorders
- Orthopedic disorders
- Ophthalmic disorders
- Pain disorders
- Respiratory disorders
- Other therapeutic areas
Key geographical regions
- North America
- Europe
- Asia Pacific
- Rest of the world
The report also includes information on insights provided by the following industry experts:
- Raghu Vadlamudi (Chief Research and Technology Director, Donatelle)
- Jan Wahlström (President and Chief Executive Officer, Elos Medtech)
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Global Antibody Drug Conjugates Market Research Report 2020-2030
The ‘Antibody Drug Conjugates Market (5th Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade.
To order this detailed 600+ page report, please visit this link
Key Inclusions
- A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency.
- Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.
- An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
- A list of key opinion leaders (KOLs) within this domain, featuring detailed 2X2 matrices to assess the relative experience of key individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations and strength of professional network (based on information available on LinkedIn).
- An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials.
- An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant agreements.
- An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing ADCs.
- An in-depth analysis of the various patents that have been filed / granted related to ADCs till May 2019. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
- A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April), highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations.
- An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products.
- An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®.
- An assessment of the various therapeutics that are being evaluated in combination with ADCs. The study also presents the likely evolution of these therapeutics across different indications.
- A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations; in addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.
- An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. It also includes an analysis of the different methods used in estimating FIH doses. In addition, it highlights the possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD).
- An elaborate discussion on various factors that form the basis for the pricing of ADC products, featuring different models / approaches that pharmaceutical companies may choose to adopt while deciding the price of their respective lead therapy candidates that are likely to be marketed in the coming years.
- A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
- A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving ADCs, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of Payload
- MMAE
- DM4
- Camptothecin
- DM1
- MMAF
- Others
Type of Linker
- VC
- Sulfo-SPDB
- SMCC
- VA
- Hydrazone
- Others
Target Indication
- Breast cancer
- Lymphoma
- Leukemia
- Urothelial cancer
- Lung cancer
- Ovarian cancer
- Others
Target Antigen
- CD30
- HER2
- CD22
- CD33
- Others
Technology Providers
- Seattle Genetics
- ImmunoGen
- StemCentRx
- Immunomedics
- Others
Key Geographical Regions
- North America
- Europe
- Asia Pacific
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
- Alan Burnett (Professor, School of Medicine, Cardiff University)
- Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
- Anthony DeBoer (Director, Business Development, Synaffix)
- Christian Bailly (Director of CDMO, Pierre Fabre)
- Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
- Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
- John Burt (Chief Executive Officer, Abzena)
- Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
- Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
- Mark Wright (Site Head, Piramal Healthcare)
- Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
- Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
- Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)
- Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Next Generation Contact Lenses Market Worth USD 3.7 billion by 2030 | Roots Analysis
Advancements in the domain of ophthalmology continue to expand the range of potential application areas for contact lenses. Presently, over 55 novel ophthalmic products have been developed or are being developed for the treatment of various ophthalmological disorders, diagnosis / monitoring of diseases and for restoring vision in the blind. The ongoing efforts to innovate in this domain are evident from the fact that more than 7,500 patents have been granted / filed since 2013.
To order this 230+ page report, which features 115+ figures and 110+ tables, please visit this link
The USD 3.7 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:
Type of Product
- Contact Lenses
- Visual Prostheses
Type of Lenses
- Therapeutic Contact Lenses
- Drug-eluting Contact Lenses
- Diagnostics and Monitoring Contact Lenses
Target Indication
- Age-related Macular Degeneration
- Aniridia
- Diabetes
- Glaucoma
- Retinitis Pigmentosa
Key Geographical Region
- North America
- EU5
- Asia-Pacific
The Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030 report features the following technologies, which we identified to be key players in this domain:
- EyePrint Prosthetics
- University of Washington
- Leo Lens Technology
- Baylor College of Medicine
- iBIONICS
Table of Contents
- Preface
- Executive Summary
- Introduction
- Market Overview
- Promotional Analysis
- Technology Profiles
- Patent Analysis
- Partnerships and Collaborations
- Emerging Trends on Social Media
- KOL Analysis
- Market Sizing and Forecast
- Interview Transcripts
- Conclusion
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Medical Device CROs Market is Expected to Reach 15.7 billion by 2030
Given the complex R&D protocols and the increasing demand for clinical evidence of therapeutic benefit, there seems to be a lucrative opportunity for contract research providers engaged in the medical devices’ domain. In fact, since 2000, 150 new CROs have been established that offer a variety of cost-efficient services and solutions to medical device developers.
To order this 400+ page report, which features 240+ figures and 200+ tables, please visit this link
The USD 15.7 billion (by 2030) financial opportunity within the antibody contract manufacturing market has been analyzed across the following segments:
Phase of Development
- Clinical
- Preclinical
Types of Preclinical Services Offered
- Biocompatibility testing
- Sterility and microbiology testing
- Material characterization and analytical services
- Others
Types of Clinical Services Offered
- Clinical trial management
- Data management
- Regulatory affairs management
- Consulting
- Others
Device Class
- Class I medical devices
- Class II medical devices
- Class III medical devices
Target Therapeutic Area
- CNS disorders
- Cardiovascular disorders
- Oncological disorders
- Bone disorders
- Respiratory disorders
- Pain management disorders
- Ophthalmic disorders
- Psychological disorders
- Metabolic disorders
- Others
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
The Medical Device CROs Market (2nd Edition), 2020 - 2030 report features the following companies, which we identified to be key players in this domain:
- Avania (formerly known as Factory CRO)
- Charles River Laboratories
- Clinlogix
- CROMSOURCE
- CSSi LifeSciences™
- Eurofins Medical Device Testing
- genae
- IMARC Research
- IQVIA
- Medpace
- NAMSA
- Qserve Group
- Regulatory and Clinical Research Institute (now a part of Covance)
- WuXi AppTec
Table of Contents
- Preface
- Executive Summary
- Introduction
- Market Landscape
- Regulatory and Reimbursement Landscape for Medical Devices
- Company Profiles
- Medical Device Developer and CRO Relationships: Key Value Drivers and Performance Indicators
- Competitive Benchmarking
- Brand Positioning of Key Industry Players
- Clinical Trial Analysis
- Mergers and Acquisitions
- Survey Insights
- Market Sizing and Forecast
- Case Study: Impact of Coronavirus Outbreak
- SWOT Analysis
- Future Trends and Opportunities
- Interview Transcripts
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
COVID-19 Update | Medical Device Contract Manufacturing Market: Research Reveals Enhanced Growth During The Forecast Period 2030
More than 100 medical devices were approved by the FDA in 2018, while several are currently being evaluated across more than 9,500 (active) clinical trials, worldwide. Further, increase in aging population, coupled with rise in the prevalence of chronic disorders, are likely to drive the demand for medical devices. Therefore, in order to reduce the overall cost and expedite the time to market, majority of original equipment manufacturers (OEMs) are outsourcing their medical device manufacturing operations to CMOs.
To order this 590+ page report, which features 275+ figures and 290+ tables, please visit this link
The USD 126 billion (by 2030) financial opportunity within the medical device contract manufacturing market has been analyzed across the following segments:
Application areas
- Therapeutic devices
- Diagnostic devices
- Drug delivery devices
- Other devices
Device class
- Class I medical devices
- Class II medical devices
- Class III medical devices
Therapeutic areas
- Cardiovascular disorders
- CNS disorders
- Metabolic disorders
- Oncological disorders
- Orthopedic disorders
- Ophthalmic disorders
- Pain disorders
- Respiratory disorders
- Other therapeutic areas
Key geographical regions
- North America
- Europe
- Asia Pacific
- Rest of the world
The Medical Device Contract Manufacturing Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:
- Cirtec Medical
- Creganna Medical
- DynaFlex Technologies
- Europlaz Technologies
- Interplex
- I-Tek Medical Technologies
- Keystone Solutions Group
- Modern Medical
- Oscor
- Providence Enterprise
- Riverside Medical Packaging
- SMC
- Stellartech
- Suzhou Jenitek
- Synecco
- Trelleborg Sealing Solutions
Table of Contents
- Preface
- Executive Summary
- Introduction
- Regulatory Landscape for Medical Devices
- Market Overview: Therapeutic Devices
- Market Overview: Diagnostic Devices
- Market Overview: Delivery Systems and Others
- Benchmark Analysis
- Supply Chain Analysis
- Company Profiles
- Clinical Trial Analysis
- Mergers and Acquisitions
- Case Study: Offshoring Medical Device Contract Manufacturing
- Market Forecast
- SWOT Analysis
- Conclusion
- Survey / Interview Transcripts
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Autoinjectors Market Headed for Growth and Global Expansion by 2030
In addition to enabling patients to self-medicate, these devices are designed to ensure safety during the dosing process and promote compliance to prescribed therapeutic regimens. Moreover, the adoption of autoinjectors, and other self-injection products, has enabled significant cost savings for end users by eliminating the need to visit hospitals / out-patient clinics for dosing.
To order this 600+ page report, which features 360+ figures and 350+ tables, please visit this link
The USD 2.5 billion (by 2030) financial opportunity within the global autoinjectors market has been analyzed across the following segments:
Usability
- Disposable
- Reusable
Route of administration
- Subcutaneous
- Intramuscular
Type of molecule
- Antibody
- Peptide
- Protein
- Small molecule
Therapeutic indication
- Anaphylaxis
- Diabetes
- Migraine
- Multiple sclerosis
- Rheumatoid arthritis
- Other indications
Key geographical regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
The Global Autoinjectors Market (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Antares Pharma
- Consort Medical (Previously Bespak)
- DALI Medical Devices
- Elcam Medical (E3D Elcam Drug Delivery Devices)
- Jiangsu Delfu Medical Devices
- Oval Medical Technologies
- Owen Mumford
- SHL Group
- Union Medico®
- Ypsomed
Table of Contents
- Preface
- Executive Summary
- Introduction
- Primary Drug Containers
- Autoinjectors: Current Market Landscape
- Product Competitiveness Analysis
- Brand Positioning of Key Industry Players
- Patent Analysis
- Therapeutic Products Available in Autoinjectors
- Case Study: Autoinjector-based Combination Products and Affiliated Therapeutic Areas
- Likely Drug Candidates for Delivery Via Autoinjectors
- Key Players
- Emerging Players
- KOL Analysis
- SWOT Analysis
- Case Study: Medical Device Contract Service Providers
- Market Sizing and Opportunity Analysis
- Conclusion
- Interview Transcripts
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Antibody Drug Conjugates Market Research Report 2020-2030
With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.
To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link
The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:
Type of Payload
- MMAE
- DM4
- Camptothecin
- DM1
- MMAF
- Others
Type of Linker
- VC
- Sulfo-SPDB
- SMCC
- VA
- Hydrazone
- Others
Target Indication
- Breast cancer
- Lymphoma
- Leukemia
- Urothelial cancer
- Lung cancer
- Ovarian cancer
- Others
Target Antigen
- CD30
- HER2
- CD22
- CD33
- Others
Technology Providers
- Seattle Genetics
- ImmunoGen
- StemCentRx
- Immunomedics
- Others
Key Geographical Regions
- North America
- Europe
- Asia Pacific
The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:
- Bristol Myers Squibb
- GlaxoSmithKline
- Incyte
- Novartis
- Trillium Therapeutics
Table of Contents
- Preface
- Executive Summary
- Introduction
4.Market Overview
- Company and Drug Profiles
- Key Therapeutic Areas
- Key Opinion Leaders
- Target Competitiveness Analysis
- Partnerships and Collaborations
- Funding and Investment Analysis
- Patent Analysis
- Academic Grants
- Key Commercialization Strategies
- Promotional Analysis
- Combination Therapies
- Novel Conjugation Technology Platforms
- Assessment of Non-Clinical Data, First in Human Dosing
- Cost Price Analysis
- Case Study: Contract Manufacturing of ADC
- Case Study: Companion Diagnostics for ADC Therapeutic
- Market Forecast and Opportunity Analysis
- Swot Analysis
- Conclusion
- Executive Insights
- Appendix 1: Tabulated Data
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
